Strategic roadmaps, health economics, and market access

• Deeper characterisation of unmet need and the value proposition;
• More than a gap analysis, we subject the evidence package to a mock HTA review for a clear-eyed appraisal;
• ‘What-must-be-true’ analyses from targeted populations and pricing corridors back to the evidence;
• A comprehensive evidence generation roadmap that ranks next steps by impact and resources required;
• Communication-ready strategic recommendations that chart a path from optimised evidence to enhanced access.

You will be able to plan with confidence the required activities that will secure access for patients while meeting commercial objectives.

• Disease-specific registry collaborations and real-world evidence (RWE) analysis to close critical evidence gaps that can undermine a launch;
• Systematic literature reviews (SLR) to supplement the evidence base and power indirect comparative evidence techniques;
• Survival analysis and extrapolation to characterise long-term clinical outcomes beyond trial horizons;
• Indirect treatment comparisons (ITCs) using network meta-analysis (NMA), matching-adjusted indirect comparisons (MAIC), and simulated treatment comparisons (STC) to generate comparative effectiveness evidence where head-to-head trial data are unavailable.

You will be able to robustly defend the value proposition of any asset, with a rationalised narrative supported by compelling evidence.

• Early economic models to explore pricing corridors and identify high-leverage parameters;
• Technically rigorous cost-effectiveness models that can withstand the greatest scrutiny to convincingly demonstrate value to payers;
• Budget impact models to secure reimbursement eligibility and de-risk national HTA review procedures;
• Rapid country adaptations to empower local affiliate teams to accelerate global revenue;
• Bespoke commercial models to demonstrate net present value of an asset or portfolio to investors.

You will be ready to demonstrate that reimbursement conditions are commensurate with added clinical benefit to any audience and secure the most favourable access for patients.

• Global value dossiers to ensure a coherent value narrative with a compelling evidence base to de-risk the global launch sequence;
• National HTA submission dossiers, with procedural and technical support throughout the review process and price negotiations;
• Negotiation strategies for national organisations such as Canada’s pCPA or PASLU in Britain that enhance access in a world of ever-tighter reference pricing;
• Advisory boards, structured expert elicitation, and multi-criteria decision analysis (MCDA) to understand the expectations of payers, clinicians, and patients.

You will have a partner for the road to reimbursement, avoiding common access traps such as population restrictions, managed access agreements, and non-viable risk sharing.